Perella Weinberg Partners Capital Management LP purchased a new position in shares of Elanco Animal Health (NASDAQ:ELAN) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 129,496 shares of the company’s stock, valued at approximately $4,377,000.
A number of other large investors have also modified their holdings of the business. Sterling Investment Advisors Ltd. acquired a new position in shares of Elanco Animal Health during the first quarter worth about $25,000. Ropes Wealth Advisors LLC acquired a new position in shares of Elanco Animal Health during the first quarter worth about $25,000. Water Island Capital LLC acquired a new position in shares of Elanco Animal Health during the first quarter worth about $27,000. FTB Advisors Inc. acquired a new position in shares of Elanco Animal Health during the first quarter worth about $29,000. Finally, Valeo Financial Advisors LLC grew its position in shares of Elanco Animal Health by 376.7% during the second quarter. Valeo Financial Advisors LLC now owns 1,430 shares of the company’s stock worth $48,000 after buying an additional 1,130 shares in the last quarter.
ELAN traded down $0.17 on Friday, reaching $32.89. The company’s stock had a trading volume of 1,145,614 shares, compared to its average volume of 5,888,815. The business has a 50 day simple moving average of $33.37. Elanco Animal Health has a fifty-two week low of $28.00 and a fifty-two week high of $37.61.
Elanco Animal Health (NASDAQ:ELAN) last announced its quarterly earnings results on Thursday, May 9th. The company reported $0.25 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.22 by $0.03. The business had revenue of $731.10 million during the quarter, compared to analyst estimates of $743.40 million. The business’s revenue for the quarter was down .7% compared to the same quarter last year. During the same period last year, the company earned $0.33 earnings per share.
A number of equities analysts have recently commented on ELAN shares. BMO Capital Markets boosted their price objective on Elanco Animal Health from $32.00 to $35.00 and gave the stock a “market perform” rating in a research report on Friday, May 10th. Guggenheim started coverage on Elanco Animal Health in a research report on Wednesday, May 22nd. They set a “neutral” rating for the company. Finally, Zacks Investment Research downgraded Elanco Animal Health from a “buy” rating to a “hold” rating in a research report on Wednesday, July 10th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and six have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $33.56.
In other Elanco Animal Health news, Director John P. Bilbrey purchased 7,750 shares of the stock in a transaction that occurred on Monday, May 13th. The stock was purchased at an average cost of $32.39 per share, with a total value of $251,022.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Elanco Animal Health Profile
There is no company description available for Elanco Animal Health Inc
Read More: How to Invest in Marijuana Stocks
Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health (NASDAQ:ELAN).
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.